Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro
Senem Merve Fred, Suvi Kuivanen, Hasan Uğurlu, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Mechanisms of action of fluvoxamine for COVID-19: a historical review
Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto
Molecular Psychiatry (2022) Vol. 27, Iss. 4, pp. 1898-1907
Open Access | Times Cited: 109
SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study
Mikael Knip, Anna Parviainen, Maaret Turtinen, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 4, pp. 251-260
Open Access | Times Cited: 31
Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study
Nicolas Hoertel, Marina Sánchez‐Rico, Erich Gulbins, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 31
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Gupta, Oleksandr V. Savytskyi, Matt Coban, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101151-101151
Open Access | Times Cited: 30
Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19
Nicolas Hoertel, Marina Sánchez‐Rico, Johannes Kornhuber, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5882-5882
Open Access | Times Cited: 24
Molecular docking as a tool for the discovery of novel insight about the role of acid sphingomyelinase inhibitors in SARS- CoV-2 infectivity
Samar Sami Alkafaas, Abanoub Mosaad Abdallah, Mai Helmy Hassan, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model
David Péricat, Stephen Adonai Leon‐Icaza, Marina Sánchez‐Rico, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13623-13623
Open Access | Times Cited: 22
Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study
Irene Visos‐Varela, Maruxa Zapata‐Cachafeiro, María Piñeiro‐Lamas, et al.
European Neuropsychopharmacology (2023) Vol. 71, pp. 96-108
Open Access | Times Cited: 13
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study
Bruce Kirenga, Levicatus Mugenyi, Marina Sánchez‐Rico, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 12, pp. 5411-5418
Open Access | Times Cited: 12
Patients with psychosis spectrum disorders hospitalized during the COVID-19 pandemic unravel overlooked SARS-CoV-2 past infection clustering with HERV-W ENV expression and chronic inflammation
Ryad Tamouza, Urs Meyer, Alexandre Lucas, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France
Nicolas Hoertel, Marina Sánchez‐Rico, Pedro de la Muela, et al.
Biological Psychiatry Global Open Science (2022) Vol. 3, Iss. 1, pp. 56-67
Open Access | Times Cited: 19
Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach**
Milan Senćanski, Vladimir Perović, Jelena Мilićević, et al.
ChemistryOpen (2022) Vol. 11, Iss. 2
Open Access | Times Cited: 19
Bromodomains in Human-Immunodeficiency Virus-Associated Neurocognitive Disorders: A Model of Ferroptosis-Induced Neurodegeneration
Adonis Sfera, Karina G. Thomas, Christina V. Andronescu, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 17
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
Podjanee Jittamala, Simon Boyd, William HK Schilling, et al.
EClinicalMedicine (2025) Vol. 80, pp. 103036-103036
Open Access
Generation of RNA aptamers against chikungunya virus E2 envelope protein
Kaku Goto, R. S. Amano, Ichinose Akiko, et al.
Journal of Virology (2025)
Closed Access
Identification of potential SARS-CoV-2 inhibitors among well-tolerated drugs using drug repurposing and in vitro approaches
Betül Oruçoğlu, İdi̇l Çeti̇n, Cem Şimşek, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use
Vitória Segabinazzi Foletto, Taciéli F. da Rosa, Marissa Bolson Serafin, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 10, pp. 1601-1611
Open Access | Times Cited: 15
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
Podjanee Jittamala, Simon Boyd, William HK Schilling, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients’ variants
Tuba Khawaja, Mikael Kajova, Iris Levonen, et al.
Infectious Diseases (2024) Vol. 56, Iss. 6, pp. 423-433
Open Access | Times Cited: 3
Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection
Alexander J. McAuley, Petrus Jansen van Vuren, Muzaffar-Ur-Rehman Mohammed, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2417-2417
Open Access | Times Cited: 13
Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study
Nicolas Hoertel, Katayoun Rezaei, Marina Sánchez‐Rico, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 8, pp. 1107-1107
Open Access | Times Cited: 8
β-arrestins and G protein-coupled receptor kinases in viral entry: A graphical review
Melissa S. Maginnis
Cellular Signalling (2022) Vol. 102, pp. 110558-110558
Open Access | Times Cited: 12
Drug-induced phospholipidosis is not correlated with the inhibition of SARS-CoV-2 - inhibition of SARS-CoV-2 is cell line-specific
Viktoria Diesendorf, Valeria Roll, Nina Geiger, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants
Oleg O. Glebov
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 15
Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes
Iwona Karwaciak, Kaja Karaś, Anna Sałkowska, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3651-3651
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top